Skip to main content

Securities Firm Ups ABI s Stock, Share Price Target on Strong Fiscal Q3 Earnings

NEW YORK, April 28 (GenomeWeb News) - Piper Jaffray yesterday increased Applied Biosystems' 12-month share price target yesterday and increased the company's rating to 'Outperform.'


The securities firm now expects ABI's shares to reach $33 within 12 months. It had expected it to reach $27. The stock closed up to $28.50 yesterday.


As GenomeWeb News reported yesterday, ABI said that fiscal third-quarter sales increased 8 percent as R&D spending declined 6 percent and profits surged 121 percent.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.